CAS 749269-83-8: 1-(3',4'-Dichloro-2-fluoro-4-biphenylyl)cyclopropanecarboxylic acid

Itanapraced (CHF5074), a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).

Itanapraced is a pharmaceutical compound classified as a dopamine receptor modulator, primarily sourced through synthetic chemistry processes in advanced laboratory settings. It operates by selectively binding to dopamine receptors, thereby modulating their activity to either enhance or inhibit neurotransmission depending on the specific receptor subtype targeted. The compound's primary application lies in psychiatric and neurological research, where it is employed to explore the intricacies of dopamine-related disorders such as schizophrenia, bipolar disorder, and Parkinson's disease. By dissecting the pathways involved in these conditions, Itanapraced aids in elucidating the underlying mechanisms that govern dopamine signaling. This facilitates the development of more specific therapeutic strategies aimed at correcting dopaminergic imbalances. Its distinctive mode of action provides researchers with the flexibility to assess both agonistic and antagonistic effects within the central nervous system, extending its utility across various experimental frameworks.

Itanapraced